Published in BMC Neurosci on January 07, 2013
Nuclear receptor coactivators: regulators of steroid action in brain and behaviour. J Neuroendocrinol (2013) 0.80
Isoform switching of steroid receptor co-activator-1 attenuates glucocorticoid-induced anxiogenic amygdala CRH expression. Mol Psychiatry (2016) 0.76
Cortical plasticity following stripe rearing in the marsupial Monodelphis domestica: Neural response properties of V1. J Neurophysiol (2016) 0.76
C-fos down-regulation inhibits testosterone-dependent male sexual behavior and the associated learning. Eur J Neurosci (2013) 0.75
A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res (2001) 124.61
A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell (1996) 11.02
Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem (2010) 8.09
Nova regulates brain-specific splicing to shape the synapse. Nat Genet (2005) 6.58
Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med (2011) 5.91
Protoplasmic astrocytes in CA1 stratum radiatum occupy separate anatomical domains. J Neurosci (2002) 5.14
Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev (2010) 3.02
Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest (2006) 3.00
Transcription factor AP1 potentiates chromatin accessibility and glucocorticoid receptor binding. Mol Cell (2011) 2.97
Isoforms of steroid receptor co-activator 1 differ in their ability to potentiate transcription by the oestrogen receptor. EMBO J (1998) 2.44
Structure and function of dopamine receptors. Neurosci Biobehav Rev (2000) 2.40
Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet (2003) 2.17
2'-O-methyl-modified RNAs act as TLR7 antagonists. Mol Ther (2007) 1.85
Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res (2011) 1.84
Functional coordination of alternative splicing in the mammalian central nervous system. Genome Biol (2007) 1.80
Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy. J Neurosci (2009) 1.64
Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. Am J Hum Genet (2003) 1.52
Chronic stress alters the density and morphology of microglia in a subset of stress-responsive brain regions. Brain Behav Immun (2010) 1.49
Central amygdala glucocorticoid receptor action promotes fear-associated CRH activation and conditioning. Proc Natl Acad Sci U S A (2008) 1.41
Cellular uptake and intracellular trafficking of antisense and siRNA oligonucleotides. Bioconjug Chem (2011) 1.32
Preclinical PK and PD studies on 2'-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model. Mol Ther (2010) 1.32
Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells. Gene Ther (2004) 1.31
Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands. Genes Brain Behav (2009) 1.29
Quantitative RT-PCR gene expression analysis of laser microdissected tissue samples. Nat Protoc (2009) 1.27
Cellular uptake and intracellular fate of antisense oligonucleotides. Trends Cell Biol (1992) 1.22
Suppression of immunostimulatory siRNA-driven innate immune activation by 2'-modified RNAs. Biochem Biophys Res Commun (2007) 1.21
Diverse microglial responses after intrahippocampal administration of lipopolysaccharide. Glia (2006) 1.16
The central nucleus of the amygdala and corticotropin-releasing factor: insights into contextual fear memory. J Neurosci (2009) 1.15
Differential expression and regional distribution of steroid receptor coactivators SRC-1 and SRC-2 in brain and pituitary. Endocrinology (2000) 1.15
BDNF and glucocorticoids regulate corticotrophin-releasing hormone (CRH) homeostasis in the hypothalamus. Proc Natl Acad Sci U S A (2012) 1.13
The biological effect of an antisense oligonucleotide depends on its route of endocytosis and trafficking. Oligonucleotides (2010) 1.13
Identification and characterisation of a novel splice variant of the human CB1 receptor. FEBS Lett (2005) 1.08
Targeting several CAG expansion diseases by a single antisense oligonucleotide. PLoS One (2011) 1.08
Acute disruption of select steroid receptor coactivators prevents reproductive behavior in rats and unmasks genetic adaptation in knockout mice. Mol Endocrinol (2002) 1.06
Alternating 2'-O-ribose methylation is a universal approach for generating non-stimulatory siRNA by acting as TLR7 antagonist. Immunobiology (2009) 1.06
Steroid receptor coactivator-1 splice variants differentially affect corticosteroid receptor signaling. Endocrinology (2004) 1.01
Nuclear receptor coregulators differentially modulate induction and glucocorticoid receptor-mediated repression of the corticotropin-releasing hormone gene. Endocrinology (2007) 1.00
Steroid receptor coactivator-1 is necessary for regulation of corticotropin-releasing hormone by chronic stress and glucocorticoids. Proc Natl Acad Sci U S A (2009) 0.99
Antisense oligonucleotides and spinal muscular atrophy: skipping along. Genes Dev (2010) 0.98
Off-target effects related to the phosphorothioate modification of nucleic acids. ChemMedChem (2010) 0.95
Who's in charge? Nuclear receptor coactivator and corepressor function in brain and behavior. Front Neuroendocrinol (2009) 0.94
Region-specific involvement of BDNF secretion and synthesis in conditioned taste aversion memory formation. J Neurosci (2011) 0.91
Repair of pre-mRNA splicing: prospects for a therapy for spinal muscular atrophy. RNA Biol (2010) 0.89
Expression profiling in laser-microdissected hippocampal subregions in rat brain reveals large subregion-specific differences in expression. Eur J Neurosci (2004) 0.89
The central amygdala nucleus via corticotropin-releasing factor is necessary for time-limited consolidation processing but not storage of contextual fear memory. Neurobiol Learn Mem (2010) 0.87
A molecular blueprint of gene expression in hippocampal subregions CA1, CA3, and DG is conserved in the brain of the common marmoset. Hippocampus (2009) 0.87
Antisense-mediated RNA targeting: versatile and expedient genetic manipulation in the brain. Front Mol Neurosci (2011) 0.84
Glucocorticoid-dependent phosphorylation of the transcriptional coregulator GRIP1. Mol Cell Biol (2011) 0.84
The effect of Ndrg2 expression on astroglial activation. Neurochem Int (2011) 0.82
Modulation of corticotropin releasing factor (CRF) signaling through receptor splicing in mouse pituitary cell line AtT-20--emerging role of soluble isoforms. J Physiol Pharmacol (2009) 0.81
The application of antisense oligonucleotide technology to the brain: some pitfalls. Cell Mol Neurobiol (1994) 0.80
Chemical modifications to improve uptake and bioavailability of antisense oligonucleotides. Ann N Y Acad Sci (1992) 0.79
Interactions of the mineralocorticoid receptor--within and without. Mol Cell Endocrinol (2011) 0.79
Adhesion- and migration-related side effects of phosphothioated CpG oligodeoxynucleotides. Cell Adh Migr (2009) 0.78
Dynamics of coregulator-induced conformational perturbations in androgen receptor ligand binding domain. Mol Cell Endocrinol (2011) 0.76
Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med (2007) 7.29
Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med (2011) 5.91
Human neuroblasts migrate to the olfactory bulb via a lateral ventricular extension. Science (2007) 5.23
Increased cell proliferation and neurogenesis in the adult human Huntington's disease brain. Proc Natl Acad Sci U S A (2003) 2.36
Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. Mol Ther (2011) 2.06
In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J Gene Med (2009) 1.66
MicroRNA 18 and 124a down-regulate the glucocorticoid receptor: implications for glucocorticoid responsiveness in the brain. Endocrinology (2009) 1.46
Targeted exon skipping in transgenic hDMD mice: A model for direct preclinical screening of human-specific antisense oligonucleotides. Mol Ther (2004) 1.46
Phage display screening without repetitious selection rounds. Anal Biochem (2011) 1.36
Preclinical PK and PD studies on 2'-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model. Mol Ther (2010) 1.32
Therapy Insight: is there an imbalanced response of mineralocorticoid and glucocorticoid receptors in depression? Nat Clin Pract Endocrinol Metab (2007) 1.30
Evaluation of Affymetrix Gene Chip sensitivity in rat hippocampal tissue using SAGE analysis. Serial Analysis of Gene Expression. Eur J Neurosci (2002) 1.27
The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat (2015) 1.26
Splice modulating therapies for human disease. Cell (2012) 1.26
Transcriptional response of bronchial epithelial cells to Pseudomonas aeruginosa: identification of early mediators of host defense. Physiol Genomics (2005) 1.23
Differential expression of glucocorticoid receptor transcripts in major depressive disorder is not epigenetically programmed. Psychoneuroendocrinology (2009) 1.18
Increased sensitivity of next generation sequencing-based expression profiling after globin reduction in human blood RNA. BMC Genomics (2012) 1.18
Attenuating corticosterone levels on the day of memory assessment prevents chronic stress-induced impairments in spatial memory. Eur J Neurosci (2006) 1.17
Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. Brain (2011) 1.17
Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases. Mol Ther (2013) 1.16
The effects of low levels of dystrophin on mouse muscle function and pathology. PLoS One (2012) 1.16
Central corticosteroid actions: Search for gene targets. Eur J Pharmacol (2008) 1.15
The therapeutic potential of antisense-mediated exon skipping. Curr Opin Mol Ther (2008) 1.15
A common polymorphism in the mineralocorticoid receptor modulates stress responsiveness. J Clin Endocrinol Metab (2006) 1.13
Discovery of a functional glucocorticoid receptor beta-isoform in zebrafish. Endocrinology (2007) 1.12
Disrupted corticosterone pulsatile patterns attenuate responsiveness to glucocorticoid signaling in rat brain. Endocrinology (2010) 1.10
The Pathogenesis and Therapy of Muscular Dystrophies. Annu Rev Genomics Hum Genet (2015) 1.08
Acute stress and hippocampal histone H3 lysine 9 trimethylation, a retrotransposon silencing response. Proc Natl Acad Sci U S A (2012) 1.08
Targeting several CAG expansion diseases by a single antisense oligonucleotide. PLoS One (2011) 1.08
The developmental impact of prenatal stress, prenatal dexamethasone and postnatal social stress on physiology, behaviour and neuroanatomy of primate offspring: studies in rhesus macaque and common marmoset. Psychopharmacology (Berl) (2010) 1.07
Homodimerization of the glucocorticoid receptor is not essential for response element binding: activation of the phenylethanolamine N-methyltransferase gene by dimerization-defective mutants. Mol Endocrinol (2003) 1.07
Exploring the transcriptome of ciliated cells using in silico dissection of human tissues. PLoS One (2012) 1.06
Differences in basal and stress-induced HPA regulation of wild house mice selected for high and low aggression. Horm Behav (2003) 1.06
A genome-wide signature of glucocorticoid receptor binding in neuronal PC12 cells. BMC Neurosci (2012) 1.04
Accurate quantification of dystrophin mRNA and exon skipping levels in duchenne muscular dystrophy. Lab Invest (2010) 1.01
GeneChip analysis of hippocampal gene expression profiles of short- and long-attack-latency mice: technical and biological implications. J Neurosci Res (2003) 1.01
Stress responsiveness varies over the ultradian glucocorticoid cycle in a brain-region-specific manner. Endocrinology (2010) 1.01
Differential effects of corticosterone on the slow afterhyperpolarization in the basolateral amygdala and CA1 region: possible role of calcium channel subunits. J Neurophysiol (2007) 1.00
Steroid receptor coactivator-1 is necessary for regulation of corticotropin-releasing hormone by chronic stress and glucocorticoids. Proc Natl Acad Sci U S A (2009) 0.99
Comparison of skeletal muscle pathology and motor function of dystrophin and utrophin deficient mouse strains. Neuromuscul Disord (2012) 0.99
Early life stress paradigms in rodents: potential animal models of depression? Psychopharmacology (Berl) (2010) 0.99
Glucocorticoids modulate the mTOR pathway in the hippocampus: differential effects depending on stress history. Endocrinology (2012) 0.98
Age-related changes in hypothalamic-pituitary-adrenal axis activity of male C57BL/6J mice. Neuroendocrinology (2005) 0.98
Chromatin immunoprecipitation scanning identifies glucocorticoid receptor binding regions in the proximal promoter of a ubiquitously expressed glucocorticoid target gene in brain. J Neurochem (2008) 0.97
Serial analysis of gene expression predicts structural differences in hippocampus of long attack latency and short attack latency mice. Eur J Neurosci (2003) 0.96
Epigenetic regulation of the glucocorticoid receptor promoter 1(7) in adult rats. Epigenetics (2012) 0.96
Fibronectin is a serum biomarker for Duchenne muscular dystrophy. Proteomics Clin Appl (2014) 0.96
Exon skipping and gene transfer restore dystrophin expression in human induced pluripotent stem cells-cardiomyocytes harboring DMD mutations. Stem Cells Dev (2013) 0.95
Assessment of the feasibility of exon 45-55 multiexon skipping for Duchenne muscular dystrophy. BMC Med Genet (2008) 0.95
A 3 months mild functional test regime does not affect disease parameters in young mdx mice. Neuromuscul Disord (2010) 0.94
Large-scale gene expression profiling of discrete brain regions: potential, limitations, and application in genetics of aggressive behavior. Behav Genet (2003) 0.93
Dystrophin-deficient pigs provide new insights into the hierarchy of physiological derangements of dystrophic muscle. Hum Mol Genet (2013) 0.93
Selective transrepression versus transactivation mechanisms by glucocorticoid receptor modulators in stress and immune systems. Eur J Pharmacol (2008) 0.93
Elevated brain iron is independent from atrophy in Huntington's Disease. Neuroimage (2012) 0.93
Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy. BMC Med Genomics (2011) 0.92
Guidance in social and ethical issues related to clinical, diagnostic care and novel therapies for hereditary neuromuscular rare diseases: "translating" the translational. PLoS Curr (2013) 0.92
Differential targeting of brain stress circuits with a selective glucocorticoid receptor modulator. Proc Natl Acad Sci U S A (2013) 0.91
Inhibition of IL-1 Signaling by Antisense Oligonucleotide-mediated Exon Skipping of IL-1 Receptor Accessory Protein (IL-1RAcP). Mol Ther Nucleic Acids (2013) 0.91
Molecular investigation of TBP allele length: a SCA17 cellular model and population study. Neurobiol Dis (2003) 0.90
BMP antagonists enhance myogenic differentiation and ameliorate the dystrophic phenotype in a DMD mouse model. Neurobiol Dis (2010) 0.89
Autophagy is Impaired in the Tibialis Anterior of Dystrophin Null Mice. PLoS Curr (2013) 0.88
Gene therapy for Duchenne muscular dystrophy. Curr Opin Neurol (2012) 0.88
In silico discovery and experimental validation of new protein-protein interactions. Proteomics (2011) 0.88
Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy. Ann N Y Acad Sci (2009) 0.87
Flibanserin and 8-OH-DPAT implicate serotonin in association between female marmoset monkey sexual behavior and changes in pair-bond quality. J Sex Med (2012) 0.87
DMD transcript imbalance determines dystrophin levels. FASEB J (2013) 0.87
Pharmacology of glucocorticoids: beyond receptors. Eur J Pharmacol (2008) 0.87
Effect of brief corticosterone administration on SGK1 and RGS4 mRNA expression in rat hippocampus. Stress (2006) 0.87
Subregion-specific differences in translocation patterns of mineralocorticoid and glucocorticoid receptors in rat hippocampus. Brain Res (2008) 0.86
Cell-type specific regulation of myostatin signaling. FASEB J (2011) 0.86
Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: Implications for future clinical trials. Neuromuscul Disord (2010) 0.86
The effect of chronic exposure to highly aggressive mice on hippocampal gene expression of non-aggressive subordinates. Brain Res (2006) 0.85
Antisense-mediated RNA targeting: versatile and expedient genetic manipulation in the brain. Front Mol Neurosci (2011) 0.84
Specificity of glucocorticoid receptor primary antibodies for analysis of receptor localization patterns in cultured cells and rat hippocampus. Brain Res (2010) 0.84
Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon. Neurobiol Dis (2013) 0.84
Gene expression profiling to monitor therapeutic and adverse effects of antisense therapies for Duchenne muscular dystrophy. Pharmacogenomics (2006) 0.84
Two populations of glucocorticoid receptor-binding sites in the male rat hippocampal genome. Endocrinology (2013) 0.84
Antisense-oligonucleotide mediated exon skipping in activin-receptor-like kinase 2: inhibiting the receptor that is overactive in fibrodysplasia ossificans progressiva. PLoS One (2013) 0.84
Dose-dependent pharmacokinetic profiles of 2'-O-methyl phosphorothioate antisense oligonucleotidesin mdx mice. Nucleic Acid Ther (2013) 0.83
Long-term Exon Skipping Studies With 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models. Mol Ther Nucleic Acids (2012) 0.83
Less is more: therapeutic exon skipping for Duchenne muscular dystrophy. Lancet Neurol (2009) 0.83
Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification. Nucleic Acid Ther (2013) 0.82
Overview on applications of antisense-mediated exon skipping. Methods Mol Biol (2012) 0.82
TBP, a polyglutamine tract containing protein, accumulates in Alzheimer's disease. Brain Res Mol Brain Res (2004) 0.82
Glucocorticoid receptor and myocyte enhancer factor 2 cooperate to regulate the expression of c-JUN in a neuronal context. J Mol Neurosci (2012) 0.82
Ataxin-3 protein and RNA toxicity in spinocerebellar ataxia type 3: current insights and emerging therapeutic strategies. Mol Neurobiol (2013) 0.81
Paired hormone response elements predict caveolin-1 as a glucocorticoid target gene. PLoS One (2010) 0.81
Glucocorticoid-enhanced expression of dioxin target genes through regulation of the rat aryl hydrocarbon receptor. Toxicol Sci (2007) 0.81
No effect of prolonged corticosterone over-exposure on NCAM, SGK1, and RGS4 mRNA expression in rat hippocampus. Brain Res (2006) 0.80
Timing is critical for effective glucocorticoid receptor mediated repression of the cAMP-induced CRH gene. PLoS One (2009) 0.80
Ontogeny of steroid receptor coactivators in the hippocampus and their role in regulating postnatal HPA axis function. Brain Res (2007) 0.80
Smaller grey matter volumes in the anterior cingulate cortex and greater cerebellar volumes in patients with long-term remission of Cushing's disease: a case-control study. Eur J Endocrinol (2013) 0.79